As the European market navigates through a landscape marked by fluctuating trade dynamics and mixed economic signals, the pan-European STOXX Europe 600 Index has shown resilience with a recent uptick of 1.15%, despite looming tariff concerns from the U.S. In this environment, identifying promising small-cap stocks can be particularly rewarding, especially those that exhibit strong fundamentals and insider activity, which may suggest confidence in their potential amidst broader market uncertainties. Top 10 Undervalued Small Caps With Insider Buying In Europe Name PE PS Discount to Fair Value Value Rating Hoist Finance 8.7x 1.8x 20.10% ★★★★★☆ A.G. BARR 19.5x 1.8x 46.18% ★★★★☆☆ Yubico 32.4x 4.6x 12.21% ★★★★☆☆ Renold 10.6x 0.7x 3.17% ★★★★☆☆ CVS Group 44.4x 1.3x 39.97% ★★★★☆☆ Seeing Machines NA 2.7x 47.71% ★★★★☆☆ Nyab 23.4x 1.0x 32.11% ★★★☆☆☆ NOTE 21.1x 1.4x -8.58% ★★★☆☆☆ Lords Group Trading NA 0.2x -6.12% ★★★☆☆☆ Karnov Group 227.7x 4.8x 28.97% ★★★☆☆☆ Click here to see the full list of 53 stocks from our Undervalued European Small Caps With Insider Buying screener. Here we highlight a subset of our preferred stocks from the screener. Foxtons Group Simply Wall St Value Rating: ★★★★★☆ Overview: Foxtons Group is a UK-based real estate agency specializing in property sales, lettings, and financial services with a market cap of approximately £0.12 billion. Operations: Foxtons Group generates revenue primarily from Lettings (£106.03 million), Sales (£48.57 million), and Financial Services (£9.33 million). The company has experienced fluctuations in its net income margin, which was 24.76% in September 2014 but showed a decline to -15.42% by December 2018 before recovering to reach positive figures again, such as 8.54% by December 2024. Operating expenses have consistently been a significant portion of the company's costs, impacting overall profitability over time. PE: 13.7x Foxtons Group, a notable player in the European market, saw a revenue jump to £44.1 million for Q1 2025 from £35.7 million the previous year, highlighting its growth potential. Despite relying solely on external borrowing for funding, which poses higher risk, insider confidence is evident with recent share purchases by executives. The company also approved a final dividend of 0.95 pence per share in May 2025, indicating shareholder-friendly policies amidst projections of annual earnings growth at 12%. Take a closer look at Foxtons Group's potential here in our valuation report. Gain insights into Foxtons Group's historical performance by reviewing our past performance report.LSE:FOXT Share price vs Value as at Jul 2025 Zigup Simply Wall St Value Rating: ★★★★☆☆ Story Continues Overview: Zigup operates in the rental and claims services sectors, with a focus on the UK, Ireland, and Spain markets, and has a market capitalization of £1.75 billion. Operations: Zigup generates revenue primarily from UK&I Rental, Spain Rental, and Claims & Services. The company's gross profit margin has shown fluctuations, peaking at 29.54% in late 2022 before declining to 21.95% by mid-2025. Operating expenses have steadily increased over time, impacting the overall profitability of the business. PE: 9.5x Zigup's recent earnings call on July 9, 2025, revealed a mixed financial landscape. Despite a decline in net income to £79.85 million from £125.02 million the previous year, sales rose to £682.89 million from £649.27 million, indicating potential for revenue growth. Insider confidence is evident with recent share purchases by executives over the past year, suggesting optimism about future prospects despite current challenges like lower profit margins and reliance on external borrowing for funding. Navigate through the intricacies of Zigup with our comprehensive valuation report here. Understand Zigup's track record by examining our Past report.LSE:ZIG Share price vs Value as at Jul 2025 BICO Group Simply Wall St Value Rating: ★★★☆☆☆ Overview: BICO Group is a biotechnology company specializing in bioprinting, lab automation, and life science solutions with a market cap of SEK 6.15 billion. Operations: The company's revenue is derived from three primary segments: Bioprinting (SEK 401.30 million), Lab Automation (SEK 447.20 million), and Life Science Solutions (SEK 1.02 billion). The gross profit margin has shown variability, with a notable decline to 49.25% in recent periods. PE: -8.1x BICO Group, a smaller European company, faces challenges with declining earnings and reliance on external borrowing. In the first quarter of 2025, sales dropped to SEK 388.6 million from SEK 470.2 million the previous year, while net losses widened significantly to SEK 234 million. Recent executive changes include appointing Lars Risberg as General Counsel and board reshuffles. These shifts may signal strategic realignment as BICO navigates its financial hurdles and explores future growth opportunities in its industry niche. Click here to discover the nuances of BICO Group with our detailed analytical valuation report. Assess BICO Group's past performance with our detailed historical performance reports.OM:BICO Ownership Breakdown as at Jul 2025 Taking Advantage Access the full spectrum of 53 Undervalued European Small Caps With Insider Buying by clicking on this link. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world. Seeking Other Investments? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LSE:FOXT LSE:ZIG and OM:BICO. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected] View Comments
Exploring 3 Promising Undervalued Small Caps With Insider Activity In The European Market
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...